Evaluating comparative and equality judgments in contrast perception: attention alters appearance

Covert attention not only improves performance in many visual tasks but also modulates the appearance of several visual features. Studies on attention and appearance have assessed subjective appearance using a task contingent upon a comparative judgment (e.g., M. Carrasco, S. Ling, & S. Read, 2004). Recently, K. A. Schneider and M. Komlos (2008) questioned the validity of those results because they did not find a significant effect of attention on contrast appearance using an equality task. They claim that such equality judgments are bias-free whereas comparative judgments are bias-prone and propose an alternative interpretation of the previous findings based on a decision bias. However, to date there is no empirical support for the superiority of the equality procedure. Here, we compare biases and sensitivity to shifts in perceived contrast of both paradigms. We measured contrast appearance using both a comparative and an equality judgment. Observers judged the contrasts of two simultaneously presented stimuli, while either the contrast of one stimulus was physically incremented (Experiments 1 and 2) or exogenous attention was drawn to it (Experiments 3 and 4). We demonstrate several methodological limitations of the equality paradigm. Nevertheless, both paradigms capture shifts in PSE due to physical and perceived changes in contrast and show that attention enhances apparent contrast.     

Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma

Classic interferon-α formulations have antitumour activity in a variety of neoplastic diseases, including the adjuvant and palliative setting of metastatic melanoma, as single agents or in combination with chemotherapy and/or interleukin-2. Pegylated interferon, widely used for the treatment of hepatitis, seems to be at least equally efficacious as standard recombinant interferon in the treatment of metastatic melanoma, and the available evidence suggests that equi-efficacious doses have somewhat lower acute toxicity. Moreover, the favourable pharmacokinetic properties of pegylated interferon allow the administration on a weekly basis, with sustained exposure to interferon during that entire period.Several clinical trials have been conducted testing adjuvant and palliative treatment with pegylated interferon-α in high-risk melanoma patients with promising results. The role of pegylated interferons in the setting of advanced metastatic melanoma will need further investigation in clinical trials, potentially in combination with targeted or cytotoxic agents with regard to synergistic antiangiogenic and cytotoxic effects. The use of pegylated interferons in earlier stage melanomas will be investigated in upcoming trials.     

Insulin‐like growth factor‐1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus

Insulin‐like growth factor‐1 receptor (IGF‐1R) and human epidermal growth factor receptor‐2 (HER2) receptor expression has been found to be a key regulator of tumorigenesis. The purpose of our study was to establish the prognostic significance of IGF‐1R in esophageal cancer and to determine the effect of IGF‐1R and HER2 targeting with α‐IR3 and Herceptin? antibodies on the proliferation of esophageal cancer cells in vitro. IGF‐1R expression and clinicopathological correlations were analyzed with a tissue microarray containing 234 esophageal cancer specimens (133 adenocarcinomas and 101 squamous cell carcinomas). Proliferation changes associated with Herceptin? and α‐IR3 blockage were evaluated with the unique human esophageal cancer cell lines Pt1590 and LN1590. IGF‐1R and HER2 expression levels, activation and phosphorylation status of downstream signaling proteins involved in the activation pathways were analyzed by Western blotting. IGF‐1R overexpression was detected in 121 (52%) of the 234 esophageal tumors examined. In the subgroup of 87 HER2‐positive tumors, 93.1% showed concordant overexpression for IGF‐1R. IGF‐1R was identified as a variable associated with reduced overall survival for adenocarcinoma (p = 0.05), but not for squamous cell carcinoma. The combination of Herceptin? and α‐IR3 was more effective in inhibiting in vitro proliferation than treatment with either agent alone (p < 0.01). This was associated with a decrease in HER2 and IGF‐1R protein levels and suppression of Akt‐ and MAP kinase phosphorylation. IGF‐1R expression can be used as a novel prognostic marker for adenocarcinomas of the esophagus. Cotreatment with IGF‐1R and HER2 antibodies might become a valuable and effective treatment option in esophageal adenocarcinoma.     

Dietary intake and plasma concentrations of PUFA and LC-PUFA in breastfed and formula fed infants under real-life conditions

Background  

The breastfed infant is usually used as standard for formula feeding, also regarding long-chain polyunsaturated fatty acids (LC-PUFA). Here, plasma fatty acid concentrations in formula fed infants and the effects of LC-PUFA supplementation were investigated under real-life conditions.     

Glutamine as indispensable nutrient in oncology: experimental and clinical evidence

Background  

In hypermetabolic situations, glutamine is intensively used by rapidly dividing cells such as enterocytes, lymphocytes, and fibroblasts as nitrogen source and/or alternative energy fuel. It is hypothesized that in cancer patients the increased glutamine demands of the host increase the capacity of endogenous production resulting in a strong glutamine deprivation with detrimental effects on organ functions. In long-term periods of cancer cachexia, an adequate nutrition support including glutamine can essentially contribute to cover glutamine needs and, thus, to spare energy reserves of the host and to retard severe complications such as multi-organ failure. Due to the early in vitro knowledge that cancer cells preferably consume glutamine, oncologists often refuse to supply glutamine to the tumor-bearing host to avoid any potential risk. An objective evaluation whether supplemental glutamine supports tumor growth in vivo is, however, still lacking.     

The prevalence of current sunbed use and user characteristics: the SUN-Study 2008

Objectives  

Although sunbed use is common in many developed countries, little is known about the characteristics of sunbed users.